



Joe Lombardo
Governor

NEVADA HEALTH AUTHORITY

Nevada Medicaid

4070 Silver Sage Drive
Carson City, NV 89701

NVHA.NV.GOV



Stacie Weeks, Director

Ann Jensen, Administrator

Drug Utilization Review Board Meeting Minutes

Date of Meeting: Thursday, July 31, 2025

Name of Organization: The State of Nevada, Nevada Health Authority, Nevada Medicaid, Drug Use Review Board

Agenda Item	Record	Notes																								
1) Call to Order and Roll Call	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Jennifer Wheeler called the meeting to order at 1:00 p.m. on July 31, 2025.</p> <p>Chairperson Wheeler took the roll.</p> <table> <tr> <th></th><th>Present</th><th>Absent</th></tr> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> </table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<p>Nevada Medicaid Staff Present were as follows:</p> <ul style="list-style-type: none"> • Brown, Antonio, Chief of Pharmacy & DMEPOS • Palomino, Bonnie, Pharmacy Services Manager • Flowers, Ellen, Social Services Program Specialist II • Cabrera, Donna, Program Officer I • Hamilton, Jessica, DMEPOS Program Manager • Driscoll, Lauren, Deputy Attorney General (DAG) <p>Prime Therapeutics Staff Present were as follows:</p> <ul style="list-style-type: none"> • Czechowski, Jessica, Pharm.D., Director, Clinical Account Services • Mishra, Raj, Pharm.D., Clinical Account Manager • Deoliveira, Brittany, Pharm.D., Clinical Account Manager • Martinez, Chris, Sr. Business Analyst
	Present	Absent																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																								
• Brain Le, DO	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								

		<p>Managed Care Organization representatives present were as follows:</p> <ul style="list-style-type: none">• Bitton, Ryan, Pharm.D., Health Plan of Nevada• Marquez, Joy, Pharm.D., Silver Summit Health Plan• Tran, Jimmy, Pharm.D., Molina Healthcare• Ahmed, Shadi, Pharm.D., Anthem <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list’s accuracy is not assured.</p>												
2) General Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>													
3) Administrative														
a) For Possible Action: Review and Approve Meeting Minutes from April 17, 2025.	<p>Vice-Chair Neto Adeolokun moved to approve the minutes as presented, and Board Member Jessica Cate seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>											

	<ul style="list-style-type: none"> • Crystal Castaneda, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • David England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
b) Status Update by DHCFP	<p>Chief of Pharmacy and DMEPOS Antonio Brown provided an announcement.</p> <p>I just have a couple of announcements I wanted to share. So, the first one, we have officially transitioned to Nevada Health Authority under the Division of Nevada Medicaid. We are no longer DHCFP. That said, there are no changes to this board. Additionally, I would like to share that Nevada Medicaid has officially launched the Single Preferred Drug List initiative. This means that moving forward Nevada Medicaid will follow one unified PDL. The goal of this initiative is to reduce the administrative burden for providers and recipients, simplify the prioritization process, enhance continuity of care and support better healthcare outcomes for all of the Medicaid Members. We are currently in the planning phase and expect full implementation by January 1st, 2026. As a last update, we are still recruiting for our board. We are looking for active, practicing physicians and pharmacists. If you are interested, please send us your CV at rxinfo@nvha.nv.gov.</p>	

4) Clinical Presentations		
a) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Niemann-Pick disease type C (NPC) agents.		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by William Lam, Scientific Director for Madrigal Pharmaceuticals.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Raj Mishra reviewed the proposed criteria presented in the binder for Aqneursa and Miplyffa.</p> <ul style="list-style-type: none"> • Dr. Ryan Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Joy Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Jimmy Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Shadi Ahmed with Anthem, approved of the proposed criteria as presented. 	
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the Board Members had any comments.</p> <p>No comments were made.</p>	

iv) Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics and Board Member Cate seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
b) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Rezdiffra (resmetirom) .																																		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>																																	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Rezdiffra.</p> <ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented with recommendations for lab work or attestation that the member has progressed to stage 4 cirrhosis be added to the renewal criteria.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.																																	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. Vice-Chair Adeolokun provided a comment. Board Member Cate provided a comment.																																	
iv) Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics with the addition of Endocrinologist prescriber or consultation option; Chairperson Wheeler seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
c) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Kisunla (donanemab-azbt) .																																		

i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comments were called for, and the phone lines were opened. Public comments were provided by Elizabeth Lobelzik, Payer Health Outcomes Liaison at Eli Lilly and Company.									
ii) Presentation of utilization and clinical information.	Dr. Mishra reviewed the proposed criteria presented in the binder for Kisunla. <ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.									
iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.									
iv) Proposed adoption of updated prior authorization criteria.	Board Member David England moved to approve the criteria as presented by Prime Therapeutics and Board Member Cate seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>							

	<ul style="list-style-type: none"> • Netochi Adeolokun, Pharm.D., Vice-Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Crystal Castaneda, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jessica Cate, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • David England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> 	
d) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Respirator and Allergy Biologics .		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Nemluvio, Ebglyss and Dupixent.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	

iii) Discussion by Board and review of utilization data.	Chairperson Wheeler asked if the Board Members had any comments. No comments were made.																																	
iv) Proposed adoption of updated prior authorization criteria.	Board Member England moved to approve the criteria as presented by Prime Therapeutics and Chairperson Wheeler seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
e) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for chenodiol .																																		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comments were called for, and the phone lines were opened. Public comment was provided by April LaRue from Marion Pharmaceuticals.																																	

ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for chenodiol.</p> <ul style="list-style-type: none">• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented.• Dr. Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented.• Dr. Ahmed with Anthem, approved of the proposed criteria as presented.																																	
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the Board Members had any comments.</p> <p>No comments were made.</p>																																	
iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member Cate moved to approve the criteria as presented by Prime Therapeutics and Chairperson Wheeler seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															

f) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Cholbam (cholic acid) .		
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by April LaRue from Marion Pharmaceuticals.</p>	
ii) Presentation of utilization and clinical information.	<p>Dr. Mishra reviewed the proposed criteria presented in the binder for Cholbam.</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 	
iii) Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked if the Board Members had any comments.</p> <p>Board Member England made a comment.</p> <p>Vice-Chair Adeolokun made a comment.</p>	

iv) Proposed adoption of updated prior authorization criteria.	<p>Board Member England moved to approve the criteria as presented by Prime Therapeutics and Vice-Chair Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
5) Board Requested Reports																																		
<p>Opioid Utilization Reports:</p> <p>i) Opioid Trends</p> <p>ii) Top Members</p> <p>iii) Top Prescribers</p> <p>iv) Top Pharmacies</p>	<ul style="list-style-type: none">• Dr. Mishra presented opioid utilization reports.• Dr. Bitton presented opioid utilization reports.• Dr. Marquez presented opioid utilization reports.• Dr. Tran presented opioid utilization reports.• Dr. Ahmed presented opioid utilization reports. <p>Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports. The Board discussed utilization and trends. No additional action taken or motions for investigative referrals.</p>																																	
<p>Comments from Board Members regarding the Opioid Utilization Reports.</p>	<p>Chairperson Wheeler asked for comments from Board Members regarding Opioid Reports.</p> <p>No additional action taken or motions for investigative referrals.</p> <p>Board Members suggested bringing some ideas to the next meeting on how to improve the process of monitoring providers.</p>																																	

Standard DUR Reports: i) Top 10 Therapeutic Classes ii) ProDUR Paid Claims Savings Report iii) RetroDUR DUR Initiatives	<ul style="list-style-type: none"> • Dr. Mishra presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports. • Dr. Marquez presented Standard DUR Reports. • Dr. Tran presented Standard DUR Reports. • Dr. Ahmed presented Standard DUR Reports. 																									
6) Physician Administered Drugs																										
a) For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for Physician Administered Drugs .	<table> <tr> <td>Bavencio</td><td>Imfinzi</td><td>Perjeta</td></tr> <tr> <td>Bevacizumab_ONCO</td><td>Jemperli</td><td>Rituximab_IV</td></tr> <tr> <td>Darzalex_IV</td><td>Kadcyla</td><td>Susvimo</td></tr> <tr> <td>Darzalex_SQ</td><td>Keytruda</td><td>Tecentriq_IV</td></tr> <tr> <td>Denosumab</td><td>Libtayo</td><td>Trastuzumab_IV</td></tr> <tr> <td>Eculizumab</td><td>Opdivo</td><td>Trastuzumab_SQ</td></tr> <tr> <td>Elaprase</td><td>Paclitaxel Albumin-Bound</td><td>Yervoy</td></tr> <tr> <td>GCSF_LA</td><td>Pemetrexed</td><td>Zynlonta</td></tr> </table>	Bavencio	Imfinzi	Perjeta	Bevacizumab_ONCO	Jemperli	Rituximab_IV	Darzalex_IV	Kadcyla	Susvimo	Darzalex_SQ	Keytruda	Tecentriq_IV	Denosumab	Libtayo	Trastuzumab_IV	Eculizumab	Opdivo	Trastuzumab_SQ	Elaprase	Paclitaxel Albumin-Bound	Yervoy	GCSF_LA	Pemetrexed	Zynlonta	
Bavencio	Imfinzi	Perjeta																								
Bevacizumab_ONCO	Jemperli	Rituximab_IV																								
Darzalex_IV	Kadcyla	Susvimo																								
Darzalex_SQ	Keytruda	Tecentriq_IV																								
Denosumab	Libtayo	Trastuzumab_IV																								
Eculizumab	Opdivo	Trastuzumab_SQ																								
Elaprase	Paclitaxel Albumin-Bound	Yervoy																								
GCSF_LA	Pemetrexed	Zynlonta																								
i) <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>Public comment was provided by Mandeep Sohal, Pharmacist with Teva.</p> <p>Public comment was provided by Kelly McNeil, Field Medical Representative with Alexion Pharmaceuticals.</p>																									
ii) Presentation of utilization and clinical information	<p>Dr. Victoria Facchini reviewed the proposed criteria presented in the binder for Physician Administered Drugs (PAD).</p> <ul style="list-style-type: none"> • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria as presented. • Dr. Marquez with Silver Summit Health Plan, approved of the proposed criteria as presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria as presented. • Dr. Ahmed with Anthem, approved of the proposed criteria as presented. 																									

iii) Proposed adoption of updated prior authorization criteria.	<p>Vice-Chair Adeolokun moved to approve the criteria as presented by Prime Therapeutics and Board Member England the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice-Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• David England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																															
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Netochi Adeolokun, Pharm.D., Vice-Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jessica Cate, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• David England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																															
• Brain Le, DO	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
• Jim Tran, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																															
7) Closing Discussion																																		
a) Public Comment	<p>Telephonic and web comments were called for, and the phone lines were opened.</p> <p>No public comments were provided.</p>																																	
b) Date and location of the next meeting.	<p>Chairperson Wheeler stated the next meeting is scheduled for October 16, 2025.</p> <p>Location: Hilton Garden Inn, Reno</p> <p>Meeting adjourned at 2:43 pm</p>																																	

Attachment A – Members of the Public in Attendance					
Aaron Girvin	Cade Grogan	JC	Lisa Pulver	Shaneka L. Wiley	Judi Ross
Ron Abraham	Camille Kerr	Jenna Artia Solutions	Robin Wells	William Lam	Rick Kegler
Stefanie Abraham	Corinne Copeland	Ashley Jones	Don Robinson	Kenneth Garcia	
Shadi A. Ahmed	Darlene Wolff	JUC (Justen Caleca)	Sabrina Schnur	Adam Furman	
Andy B	Christine Dube	Alexandra Kaiser	Samuel McKnight	Justin Clark	
Ann Marie O'Toole	Elizabeth Scott	Lori McDermott	Sofia Perez	Lee Stout	
Beth Lubelczyk	Aaron Feyos	Mandeep Sohal	Thomas Deckelman	Jill Carroll	
Angel Beus	Garth Wright	Max Wattenmaker	Jimmy Tran	April LaRow	
Brian Evans	Amy Hale	Kelly McNeil-Posey	Tray Abney	JJ Roth	
Brittany A. Aviles	Janelle Raymond	Michelle Bice	Victoria Facchini	Nate Osborne	
Attachment B – Submitted Written Comment					
None Written Comments Submitted					